



VGX Pharmaceuticals Announces Executive Promotions

Blue Bell, PA – November 7, 2007 –

VGX Pharmaceuticals announced today the promotions of Dr. Niranjn Y. Sardesai to Senior Vice President, Research & Development and Jessica C. Lee to Senior Director, Clinical Development.

Prior to this promotion, Dr. Sardesai served as VGX's Vice President of Product Development. He is an experienced veteran of the pharmaceutical industry, with a special focus on R&D and Management of Technology. Prior to joining VGX, Dr. Sardesai was the President of Nvision Consulting, Inc. He also served as the Director of R&D and Director of Applied Research at the Fujirebio Diagnostics, Inc, where he oversaw all aspects of the company's R&D activities, with a special focus on new product development. Prior to Fujirebio, he worked as a Senior Scientist at IGEN International, Inc. In his new position, Dr. Sardesai will report to Dr. J. Joseph Kim, VGX's President and CEO, and will oversee all R&D and manufacturing operations for the Company.

"Niranjn has been leading our efforts to develop a variety of products critical to the Company's growth," said Dr. Kim. "This promotion recognizes Niranjn's critical leadership efforts and I expect him to continue to manage our progress in these areas."

Dr. Sardesai received a Ph.D. in Chemistry from the California Institute of Technology and an MBA in Entrepreneurial Management from the Wharton School of the University of Pennsylvania. He also completed post-doctoral fellowships at the Scripps Research Institute and the Massachusetts Institute of Technology. Dr. Sardesai graduated at the top of his class to receive his M. Sc. in Chemistry from the Indian Institute of Technology.

Since joining the Company as Director of Clinical Development, Jessica Lee has been actively managing the development of VGX's clinical programs. In her new capacity, Ms. Lee will continue to manage the development and implementation of various clinical studies for the Company's prolific small molecule and DNA vaccines programs. She will continue to report to Dr. C. Jo White, VGX's Chief Medical Officer.

"Jessica's extensive experience and clinical management skills have been very important in leading the Company's clinical development not only for on-going clinical studies but also for preparing and initiating VGX's new clinical projects," said Dr. Kim. "She has been a true asset to our organization."

Ms. Lee has over 12 years of experience in drug and vaccine developments at several major pharmaceutical companies including Bristol-Myers Squibb, Merck, and GlaxoSmithKline. She has extensive experience in Phase I through NDA and has managed multi-center/ multi-national clinical trials. She played key roles in the development of drugs and vaccines for HIV-1, HPV, and Hepatitis B and C. Ms. Lee began her professional career as a scientist in various academic laboratories including Thomas Jefferson University and the Wistar Institute at the University of Pennsylvania. Ms. Lee received her Bachelor of Science degree in Biology from Drexel University and her Master of Science degree from Temple University School of Pharmacy.

Cautionary Factors That May Affect Future Results - Materials in this Press Release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on www.vgxp.com as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

About VGX Pharmaceuticals

VGX Pharmaceuticals is a biopharmaceutical company with small molecule and biologic product candidates for the treatment of infectious diseases, cancer, and inflammatory diseases. The Company's clinical development programs include PICTOVIR™ for HIV infection, which is in Phase II clinical trials, and PENNVAX™-B, a DNA vaccine for preventing HIV infection, which is in Phase I clinical trials. In addition, VGX is planning to initiate Phase I clinical studies for VGX-1027, its lead compound for inflammatory diseases. VGX's research pipeline includes a new generation of SynCon™ DNA vaccines and therapeutics as well as the CELLECTRA™ electroporator, a patented DNA delivery device. The product candidates and technology programs are protected by the Company's extensive global intellectual property portfolio. More information about VGX can be found at www.vgxp.com.

Company Contact:

Kevin W. Rassas

Senior Vice President

Tel. 267.440.4208

Fax 267.440.4242

E-mail: Rassas@vgxp.com

www.vgxp.com